When developing new pharmaceutical products, it is crucial to get to Phase I clinical trial in a fast, efficient and cost-effective way. Quick to Clinic^™ for Oral Solid Dose can help deliver a drug in a phase-appropriate formulation for first-in-human studies in as little as 14 weeks from API receipt to release to clinic. This process includes one-month stability testing data to help complete regulatory submissions.

Download the brochure to learn how to address early clinical development challenges, and how Quick to Clinic^™  for Oral Solid Dose can help with:

• Speed and flexibility around formulation, manufacture, and clinical labeling, packaging, and distribution
• Cost and time reduction
• Ensuring quality for first-in-human studies